首页> Journal of Clinical Oncology> Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.

Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.

导出原文传递

翻译打印收藏纠错

第一作者： Jotte R

作者： Jotte R ^[1] ; Conkling P ; Reynolds C ; Galsky MD ; Klein L ; Fitzgibbons JF ; McNally R ; Renschler MF ; Oliver JW

作者单位： Rocky Mountain Cancer Centers, 10103 Ridgegate Pkwy G-01, Lone Tree, CO 80124, USA. ^[1]

发布时间 2018-09-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Journal of Clinical Oncology

2011年29卷3期

287-293页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Journal of Clinical Oncology

2011年29卷3期

287-293页

检索历史清除

Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.

Journal of Clinical Oncology

相似文献

同项目论文

Journal of Clinical Oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.

Journal of Clinical Oncology

相似文献

同项目论文

Journal of Clinical Oncology

相关期刊

检索历史清除